Download full-text PDF

Acute respiratory distress syndrome and acute lung injury

Article · Literature Review · June 2011with376 Reads
DOI: 10.1136/pgmj.2011.118398 · Source: PubMed
Abstract
Acute respiratory distress syndrome (ARDS) is a life threatening respiratory failure due to lung injury from a variety of precipitants. Pathologically ARDS is characterised by diffuse alveolar damage, alveolar capillary leakage, and protein rich pulmonary oedema leading to the clinical manifestation of poor lung compliance, severe hypoxaemia, and bilateral infiltrates on chest radiograph. Several aetiological factors associated with the development of ARDS are identified with sepsis, pneumonia, and trauma with multiple transfusions accounting for most cases. Despite the absence of a robust diagnostic definition, extensive epidemiological investigations suggest ARDS remains a significant health burden with substantial morbidity and mortality. Improvements in outcome following ARDS over the past decade are in part due to improved strategies of mechanical ventilation and advanced support of other failing organs. Optimal treatment involves judicious fluid management, protective lung ventilation with low tidal volumes and moderate positive end expiratory pressure, multi-organ support, and treatment where possible of the underlying cause. Moreover, advances in general supportive measures such as appropriate antimicrobial therapy, early enteral nutrition, prophylaxis against venous thromboembolism and gastrointestinal ulceration are likely contributory reasons for the improved outcomes. Although therapies such as corticosteroids, nitric oxide, prostacyclins, exogenous surfactants, ketoconazole and antioxidants have shown promising clinical effects in animal models, these have failed to translate positively in human studies. Most recently, clinical trials with β2 agonists aiding alveolar fluid clearance and immunonutrition with omega-3 fatty acids have also provided disappointing results. Despite these negative studies, mortality seems to be in decline due to advances in overall patient care. Future directions of research are likely to concentrate on identifying potential biomarkers or genetic markers to facilitate diagnosis, with phenotyping of patients to predict outcome and treatment response. Pharmacotherapies remain experimental and recent advances in the modulation of inflammation and novel cellular based therapies, such as mesenchymal stem cells, may reduce lung injury and facilitate repair.
Project
To investigate the molecular composition of lung surfactant in relation to differences in air:liquid interface dynamics and respiratory physiology. To promote the understanding of an ubiquituous fu…" [more]
Article
September 2016 · Der Anaesthesist · Impact Factor: 0.76
    In dem vorliegenden Fall einer trachealen Fistel infolge einer Anastomoseninsuffizienz nach abdominothorakaler Ösophagusresektion konnte trotz Ösophagusdiskontinuitätsresektion kein operativer Fistelverschluss erfolgen. Eine vollständige Fokussanierung war somit nicht gegeben und bedurfte eines alternativen Versorgungskonzeptes in Form eines interventionellen Fistelverschlusses mittels... [Show full abstract]
    Article
    July 2009 · Medicina Intensiva · Impact Factor: 1.34
      Static pressure-volume curves of the respiratory system from patients with acute lung injury have been extensively studied as a marker of aeration and recruitment phenomena and as a tool to set mechanical ventilation. The inflection points of these curves allow to identify both the pressures in which recruitment starts and finishes and those in which derecruitment starts. However, setting the... [Show full abstract]
      Article
      December 1997 · Anesthesiology · Impact Factor: 5.88
        THE mechanisms of acute postoperative respiratory failure are usually related to incomplete recovery from anesthesia, aspiration, chronically impaired respiratory function, fluid overload, or sepsis. We report a case of unexpected postoperative respiratory distress resulting from diaphragmatic paralysis.
        Discover more